Trial intelligence / Profile preview

Phase II neoadjuvant ECF followed by weekly paclitaxel + metronomic cyclophosphamide ± trastuzumab in ER/PgR-negative locally advanced breast cancer

2009-012048-18Phase 2Completed

Sponsor: European Institute of Oncology
Start: Jul 2009
Modality: Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label trial of epirubicin, cisplatin, fluorouracil, paclitaxel, cyclophosphamide and 1 more in breast cancer (2 arms), sponsored by European Institute of Oncology. Primary endpoint: Change in Ki-67. Started Jul 2009; status: completed.

Drugs

epirubicincisplatinfluorouracilpaclitaxelcyclophosphamide

Conditions

breast cancer

Beyond the preview

Go deeper on 2009-012048-18.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-012048-18.